{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:55:59Z","timestamp":1793159759857,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"British Heart Foundation Centre of Research Excellence Grant","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}],"id":[{"id":"https:\/\/ror.org\/02wdwnk04","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Vera Melrose Heart Failure Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The prognostic significance of pulse pressure (PP) differs across HF phenotypes, but its relevance in HFmrEF remains uncertain. We evaluated associations between PP and clinical outcomes across HF phenotypes and assessed whether PP provides prognostic information beyond SBP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We performed a patient-level pooled analysis of 13 randomized HF trials including 35 550 patients with HFrEF, 6484 with HFmrEF, and 19 173 with HFpEF. PP\u2013outcome associations were assessed using Cox models for quartiles and Poisson regression with restricted cubic splines for continuous PP. Across HF phenotypes, patients with higher PP were older, more frequently female and had higher left ventricular ejection fraction and greater adiposity. In HFrEF, PP was inversely associated with first HF hospitalization or cardiovascular death, with the lowest event rate in the highest PP quartile (\u226556\u2005mmHg; 13.3 per 100 person-years [95% CI, 12.8\u201313.8]) and the highest event rate in the lowest quartile (&amp;lt;40\u2005mmHg; 18.2 [17.5\u201318.9]). In contrast, HFpEF demonstrated a J-shaped relationship, with the lowest event rate in the second quartile (48\u201356\u2005mmHg; 6.8 [6.4\u20137.3]) and the highest in the fourth quartile (&amp;gt; 66\u2005mmHg; 9.7 [9.1\u201310.3]). HFmrEF exhibited a similar J-shaped association, closely paralleling HFpEF. PP improved model fit beyond SBP, but the incremental improvement in discrimination was small and largely limited to HF hospitalization-related outcomes in HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PP has phenotype-specific prognostic implications in HF. Low PP identifies higher risk in HFrEF, whereas high PP identifies higher risk in HFpEF and HFmrEF. PP may support phenotype-specific risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag292","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:54:42Z","timestamp":1788616482000},"source":"Crossref","is-referenced-by-count":1,"title":["Phenotype-specific prognostic implications of pulse pressure in heart failure"],"prefix":"10.1093","author":[{"given":"Misato","family":"Chimura","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-9969","authenticated-orcid":false,"given":"Kieran F","family":"Docherty","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair D","family":"Henderson","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3010-5589","authenticated-orcid":false,"given":"Michel","family":"Komajda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Saint Joseph , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1828-2387","authenticated-orcid":false,"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Baylor Scott & White Health , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine-Cardiology, University of Michigan School of Medicine , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Teerlink","sequence":"additional","affiliation":[{"name":"Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universite\u0301 de Lorraine, Inserm Clinical Investigation Centre, CHU , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Zile","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ralph H. Johnson Department of Veterans Affairs Health Care System, Medical University of South Carolina , Charleston, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-5317","authenticated-orcid":false,"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026092222220474300_xuag292-B1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/01.cir.100.4.354","article-title":"Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study","volume":"100","author":"Franklin","year":"1999","journal-title":"Circulation"},{"key":"2026092222220474300_xuag292-B2","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1001\/jama.287.20.2677","article-title":"Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"287","author":"Domanski","year":"2002","journal-title":"JAMA"},{"key":"2026092222220474300_xuag292-B3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1001\/jama.281.7.634","article-title":"Increased pulse pressure and risk of heart failure in the elderly","volume":"281","author":"Chae","year":"1999","journal-title":"JAMA"},{"key":"2026092222220474300_xuag292-B4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s0735-1097(98)00679-2","article-title":"Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction","volume":"33","author":"Domanski","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"2026092222220474300_xuag292-B5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.amjcard.2003.12.011","article-title":"Relation between pulse pressure and survival in patients with decompensated heart failure","volume":"93","author":"Aronson","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026092222220474300_xuag292-B6","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/eurheartj\/ehi270","article-title":"Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure","volume":"26","author":"Voors","year":"2005","journal-title":"Eur Heart J"},{"key":"2026092222220474300_xuag292-B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00392-011-0360-x","article-title":"A low pulse pressure predicts mortality in subjects with heart failure after an acute myocardial infarction: a post-hoc analysis of the CAPRICORN study","volume":"101","author":"Petrie","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"2026092222220474300_xuag292-B8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1161\/hypertensionaha.113.02046","article-title":"Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy","volume":"63","author":"Regnault","year":"2014","journal-title":"Hypertension"},{"key":"2026092222220474300_xuag292-B9","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1093\/eurheartj\/ehu490","article-title":"Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis","volume":"36","author":"Jackson","year":"2015","journal-title":"Eur Heart J"},{"key":"2026092222220474300_xuag292-B10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jchf.2015.09.012","article-title":"Association of arterial pulse pressure with long-term clinical outcomes in patients with heart failure","volume":"4","author":"Laskey","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2026092222220474300_xuag292-B11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ahj.2014.07.008","article-title":"Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population","volume":"168","author":"Cheng","year":"2014","journal-title":"Am Heart J"},{"key":"2026092222220474300_xuag292-B12","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jacc.2024.11.007","article-title":"Systolic blood pressure and pulse pressure in heart failure: pooled participant-level analysis of 4 trials","volume":"85","author":"Lu","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026092222220474300_xuag292-B13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1161\/hypertensionaha.120.16277","article-title":"Pulse pressure, prognosis, and influence of sacubitril\/valsartan in heart failure with preserved ejection fraction","volume":"77","author":"Suzuki","year":"2021","journal-title":"Hypertension"},{"key":"2026092222220474300_xuag292-B14","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092222220474300_xuag292-B15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026092222220474300_xuag292-B16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"2026092222220474300_xuag292-B17","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026092222220474300_xuag292-B18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026092222220474300_xuag292-B19","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N Engl J Med"},{"key":"2026092222220474300_xuag292-B20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026092222220474300_xuag292-B21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092222220474300_xuag292-B22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026092222220474300_xuag292-B23","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026092222220474300_xuag292-B24","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092222220474300_xuag292-B25","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jacc.2025.08.036","article-title":"Central adiposity or hypertension: which drives heart failure with a preserved ejection fraction?","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026092222220474300_xuag292-B26","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1093\/eurheartj\/ehy346","article-title":"Pulsatile arterial haemodynamics in heart failure","volume":"39","author":"Weber","year":"2018","journal-title":"Eur Heart J"},{"key":"2026092222220474300_xuag292-B27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jama.297.7.709","article-title":"Pulse pressure and risk of new-onset atrial fibrillation","volume":"297","author":"Mitchell","year":"2007","journal-title":"JAMA"},{"key":"2026092222220474300_xuag292-B28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1161\/hypertensionaha.112.195032","article-title":"Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study","volume":"60","author":"Larstorp","year":"2012","journal-title":"Hypertension"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag292\/71031333\/xuag292.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag292\/71031333\/xuag292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:22:08Z","timestamp":1790130128000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article\/doi\/10.1093\/ejhf\/xuag292\/8790445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag292","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"xuag292"}}